# Executor handoff — Pine QA

## Assignment and boundaries

- Work ONLY in `C:\Codex\.worktrees\tradingview-cli-pinescript-qa`.
- Continue branch `codex/pine-qa`; do not create another checkout/worktree.
- Lead validated the existing product at `95a58288`; no fixes have been made.
- Resolve issues #4–#11 in `Gudals0320/tradingview-cli`, in focused commits.
- Do not merge or create a PR. Finish with a clean branch and agreement from Reviewer.
- Lead thread: `01a0f4dd-e208-7830-8122-9ae8c7280f0b`.
- The human user expressly authorizes Executor to message Lead if reproduction
  is unclear, and Executor/Reviewer to communicate as needed. Avoid routine
  updates to Lead; Lead stops polling after handoff.
- Executor requested model: GPT-6.1-Sol, High, fast on. Thread creation API can
  set model/thinking but exposes no fast-mode field; do not claim speed was set.
- Create Reviewer only when review is needed (check existing threads first).
  Same project/local directory, model `anthropic/claude-opus-5-5` (provider's
  exposed identifier for requested Opus 5.5), Medium, fast off requested.
  The user explicitly authorized creating this Reviewer thread and continued
  Executor/Reviewer messages. Review fixes against issues, request changes or
  return agreement; never merge/PR. API cannot set fast mode.

## Issues and suggested grouping

| Issue | Priority | Reproduced problem |
| --- | --- | --- |
| [#4](https://github.com/Gudals0320/tradingview-cli/issues/4) | P1 | new/open leave original document identity; save overwrites wrong script |
| [#5](https://github.com/Gudals0320/tradingview-cli/issues/5) | P1 | indicator compile succeeds before eventual compile failure |
| [#6](https://github.com/Gudals0320/tradingview-cli/issues/6) | P2 | errors counts severity-4 warnings as errors, exit 1 |
| [#7](https://github.com/Gudals0320/tradingview-cli/issues/7) | P2 | Korean save dialog left pending, command reports success |
| [#8](https://github.com/Gudals0320/tradingview-cli/issues/8) | P2 | console selectors capture editor containers and source |
| [#9](https://github.com/Gudals0320/tradingview-cli/issues/9) | P2 | analyze treats a commented strategy.entry as executable |
| [#10](https://github.com/Gudals0320/tradingview-cli/issues/10) | P2 | invalid new type overwrites current source, reports success |
| [#11](https://github.com/Gudals0320/tradingview-cli/issues/11) | P3 | raw-compile help/contract contradicts smart alias behavior |

#4/#7 concern document lifecycle and persistence, but have separate repros and
acceptance criteria. #5/#11 both touch compile but one is correctness, the other
is the exposed command contract. Keep these distinctions in commits/reviews.
Existing #2 concerns concurrent GUI editing/recovery and is outside this scope.

## Current live test environment

- Windows Store TradingView Desktop 3.4.1.8194, Korean UI; Node 24.19.0.
- Desktop restarted with `tv launch`; CDP is on `127.0.0.1:9222`.
- Disposable layout: `CLI-QA-Pine-20261001`, chart ID `kdn7wAFi`.
- At Lead handoff target ID: `358BB580C74E309A605A52D3EDC6BDF9` (ephemeral).
  Rediscover with `tv tab list`; explicitly pin target for mutations. Original
  user tabs are still open and were not used for Pine mutations.
- Disposable saved scripts: `CLI-QA-20261001 Indicator` (indicator.pine),
  `CLI-QA-20261001 Copy` (strategy.pine). Both were restored after overwrite repros.
- Current editor is bound to Copy; source is strategy.pine with one extra newline
  introduced by the PowerShell stdin pipeline. That source was saved.
- Chart contains QA indicator(s)/strategy and the initial Volume. It is purposely
  retained for Executor and can be changed freely within this QA layout.
- Do NOT use `pine open` to select a personal script before #4 is fixed.
- For creating a second QA document, UI script title menu → Make a copy was used.
  **Wait for the copy to finish and read back the source before editing**; an early
  set during UI copy completion is replaced by its async completion. This setup
  race was not filed as a product defect and is not compile-strategy evidence.

## Evidence and verification

- `TASKS.md`: all 12 commands plus full workflow attempts.
- `evidence.json`: 40 sanitized real CLI records; compiled strategy blobs and IDs
  omitted. `issues/*.md`: exact filed bodies; `issues/index.json`: remote URLs.
- `run-command.mjs LABEL ...`: actual CLI recorder, full JSON/stdout/stderr/exit
  stored in ignored `results/pine-qa/`; console preview is truncated deliberately.
- `inspect.mjs`: read-only Pine UI snapshot helper; raw output can contain private
  state. Keep snapshots in ignored results, never post unreviewed dumps.
- `summarize-evidence.mjs`: reproduces sanitized Lead evidence from recorded labels.
- `npm ci --ignore-scripts` succeeded. Baseline `TRADINGVIEW_SKIP_NETWORK_TESTS=1
  npm test`: 266 passed, 0 failed; `npm run lint` passed. Live `pine check` clean,
  invalid and warning fixtures behaved correctly.
- File set/get was byte-for-byte equal. Save/open round trip normalized CRLF to LF
  matches the original fixture. Newline normalization alone was not filed as a bug.
- Many current Pine unit tests copy implementation or inspect only UI presence;
  add regression checks of actual exported functions/CLI behavior for fixes.
- Full general-purpose E2E suite was NOT run: it manipulates broader chart/UI
  functionality outside this focused Pine workflow.

## Observed full workflow

1. Created dedicated QA layout, opened initially empty Pine editor.
2. new indicator → set/get → analyze/check → compile; real study appeared later.
3. set invalid → compile falsely succeeded → later errors exposed missing function.
4. set warning → compile → errors incorrectly failed on warning only.
5. corrected indicator → compile → save stopped at Korean dialog; list/open proved
   it was not yet saved. Clicked the observed QA save dialog button to continue.
6. Saved/reopened QA indicator; verified source, then reproduced new/save overwrite.
7. Restored QA indicator; made separate QA Copy through UI; verified actual
   strategy source → compile fresh report → compile unchanged → raw-compile unchanged.
8. From Copy, open Indicator → save → reopen Copy proved wrong-document overwrite.
9. Restored Copy strategy via stdin/save. Final errors returned no errors.

All issue titles/bodies were read back from GitHub and compared to local drafts.
Lead handoff is complete once artifacts are committed and Executor dispatched;
Lead will stop polling and await an explicit question.

## Executor results — 2026-10-01 KST

- Reviewer chat: `01a0f504-e284-7e21-be27-7c56c82b7cf6`, requested Opus 5.5 / Medium.
  Fast mode has no API field and was not verified.
- Fixes are preserved in separate commits: #9 `843739c` + `fc59f12`,
  #10 `a2caf3d`, #4 `a099564` + `ce09ca4`, #6 `6470b3b`, #8 `5aa9d92`,
  #7 `17a0f9c` + `9c99ac3`, #5 `3978948` + `7c18a9b` + `f7984bb`, #11 `8615dd3`.
- `executor-regression.mjs` asserts the actual CLI document/save round trips;
  `executor-evidence.json` omits source, script IDs, strategy blobs and user tabs.
  A new document saved/reopened correctly and retained the old A source. Opening
  A from B, editing/saving A, then reopening B retained B's source; A's update was
  present when reopened. A was restored and saved; final editor is the original
  QA Copy strategy, verified against the fixture.
- `new/open` replace unsaved editor changes without another confirmation. This
  behavior is documented in README. Actual unsaved→open and unsaved→new library
  completed promptly; indicator, strategy and library templates were accepted.
- `executor-compile-evidence.json`: saved indicator repeated compile study count
  17→17; fresh indicator first application 17→18, repeated compile retained 18.
  A pending applied indicator is awaited rather than dispatched again. Invalid
  draft compilation returned one fatal diagnostic and exit 1; correction passed.
- Editing an already saved script and compiling without `--save` now returns
  `SAVE_REQUIRED` / exit 1 before any chart or persistence action. `--save` is
  explicit permission and successful persistence is reported with `saved:true`
  and `script_id`. Draft compilation still uses Desktop's temporary draft path.
- Native save waits for completion and verifies the saved server source against
  the editor. A Korean script-name dialog is confirmed once using scoped stable
  attributes, input and title. Desktop suggests the script declaration title;
  duplicate QA titles were suffixed (`Indicator 1`, `Indicator 2`) with new IDs.
  A deliberately canceled QA name dialog returned `success:false, saved:false`.
  Timeout and interrupted-process stale lock recovery are covered by tests.
- Console QA used the overlay editor. Korean 오전 timestamps and compiler error
  levels were retained; the real `logContainer/msg` row structure was captured.
  Closing Pine Logs removed the QA log row and retained only the compiler/editor
  message. Split view was not tested. `executor-console-evidence.json` records it.
- Monaco warning markers can arrive after the native action completes. The live
  warning-only `errors` check was polled until the marker appeared; it reported
  warning_count 1, error_count 0, has_errors false and exit 0.
- Additional disposable QA saved scripts/layout studies are retained as QA
  assets, including `CLI-QA-20261001 Executor New`, suffixed Indicator documents,
  temporary Compile Repeat drafts and studies created during reproduction.
  The Canceled QA script-name dialog was canceled before saving; no named Canceled
  script was created. The final list includes 12 saved account scripts, including
  the retained QA assets; unrelated personal script contents were not changed.
  Personal scripts and the original user layouts were not changed.
- Final offline suite (network tests disabled): 297 passed, 0 failed; lint passed.
  `npm test` includes the new lifecycle, diagnostics and compilation test files.
  The broad general-purpose E2E suite remains outside this focused QA scope.
- Reviewer explicitly agreed all issues #4–#11 at `ec701a6`; the agreement is
  recorded in the reviewer chat and `EXECUTOR.md`. Only this agreement record was
  updated afterward, with the reviewer's approval and no product changes.
  No merge, PR or push was requested or performed.
